Uscom Annual Report FY2021
Continued growth and global operating cash flow positivity with expansion and investment in future revenues
Annual Report FY2021
Uscom had continued strong growth for FY21 and first operating cash flow positive year, a recognised inflection point for medical technology companies. Uscom also recorded first annual total cash receipts in excess of $5m, despite the impact of the global pandemic and ongoing global trade wars. Both China and Europe were profitable for FY21, and we have cash on hand and remain debt free. These results complete a 549% growth in total cash receipts over the prior nine trading years, at a compound annual growth rate of 23%. We are proud of these results; results that are “motivated by vision, and driven by fundamentals”. Our mission is to convert world-leading science into life-saving devices, and to create a powerful and enduringly profitable global health technology leader for the benefit of society and investors. Uscom’s results for FY21 marked significant milestones on the path to achieving these objectives.
Motivated by vision, and driven by fundamentals